TELO
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ$1.40
Mkt Cap $44.3M
52w Low $1.05
17.1% of range
52w High $3.10
50d MA $1.31
200d MA $1.42
P/E (TTM)
-4.2x
EV/EBITDA
-3.3x
P/B
7.5x
Debt/Equity
0.0x
ROE
-176.1%
P/FCF
-11.4x
RSI (14)
—
ATR (14)
—
Beta
-0.73
50d MA
$1.31
200d MA
$1.42
Avg Volume
103.5K
About
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-c…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.07 | -0.06 | +14.3% | 1.35 | -2.2% | -5.9% | -2.2% | -2.2% | -5.2% | -5.2% | -0.7% | — |
| Nov 10, 2025 | AMC | -0.07 | -0.03 | +57.1% | 1.37 | -2.2% | +3.6% | -1.5% | -5.1% | -1.5% | +2.2% | +2.9% | — |
| Aug 14, 2025 | AMC | -0.08 | -0.17 | -112.5% | 1.57 | -3.2% | -5.1% | -5.1% | -6.4% | -7.6% | -4.5% | -15.3% | — |
| May 14, 2025 | AMC | -0.10 | -0.07 | +30.0% | 2.66 | +0.4% | -11.3% | -6.0% | -4.5% | -13.9% | -19.9% | -26.3% | — |
| Feb 4, 2025 | AMC | -0.05 | -0.10 | -100.0% | 4.51 | -0.2% | +3.1% | +0.2% | -3.1% | -0.9% | -3.1% | -8.2% | — |
| Nov 12, 2024 | AMC | -0.05 | -0.20 | -300.0% | 4.19 | -2.1% | -5.0% | -5.5% | -11.0% | -21.0% | +6.0% | +21.5% | — |
| Aug 13, 2024 | AMC | — | -0.05 | — | 4.49 | -5.3% | -15.1% | -9.8% | -11.1% | +35.9% | +17.4% | +32.3% | — |
| May 13, 2024 | AMC | — | -0.23 | — | 6.66 | +0.1% | -5.3% | -6.8% | -7.2% | -7.2% | -9.3% | -17.3% | — |
| Mar 29, 2024 | AMC | — | -0.32 | — | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.06 | — | — | — | — | — | — | — | — | — | — |
Recent Filings
8-K · 8.01
!! High
Telomir Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Telomir Pharmaceuticals gained FDA clearance to begin human trials of Telomir-Zn for triple-negative breast cancer, enabling a Phase 1/2 study launch in mid-2026 at a major academic institution.
Apr 30
8-K · 2.01
!!! Very High
Telomir Pharmaceuticals, Inc. -- 8-K 2.01: Acquisition Completed
Telomir completed an acquisition that could expand its pipeline and market reach, but investors should monitor integration costs and dilution from financing used in the deal.
Apr 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Telocare's zinc-based therapeutic (Telomir-Zn) advancement signals potential clinical progress that could expand its pipeline, making it relevant for investors tracking biotech development milestones and commercialization opportunities.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
TELO filed an 8-K indicating a material event, but the vague filing details suggest potential governance or compliance updates; investors should monitor upcoming quarterly results for business impact clarification.
Mar 31
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Telomerase Therapeutics' annual shareholder meeting occurred with a January 23, 2026 record date, though the filing lacks details on voting outcomes or executive changes that could materially impact stock performance.
Mar 27
8-K · 8.01
!! High
Telomir Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Telomir Pharmaceuticals demonstrated that its Telomir-Zn candidate reduces viable tumor cells across multiple triple-negative breast cancer models through a specific mechanism, potentially validating its oncology approach.
Feb 17
8-K · 8.01
!! High
Telomir Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
Telomir Pharmaceuticals released preclinical data showing Telomir-Zn modulates cellular mechanisms related to cancer and aging through epigenetic pathways rather than cytotoxic effects, potentially broadening its therapeutic applicability.
Feb 5
Data updated apr 27, 2026 4:25am
· Source: massive.com